Topics new to this edition include the following: . Treatment-resistant depression-its definition and approaches to its treatment-is addressed in a dedicated chapter that covers diagnostic accuracy, pseudoresistance, comorbidity, pharmacological management, adjunctive strategies, psychotherapy, neuromodulation, and novel and experimental therapies.. Investigational agents, most notably ketamine and its relatives, constitute an exciting frontier in the treatment of mood disorders, and the clinical application, routes of delivery, dosing, risks, and clinical trials are explored in a dedicated chapter that is both rigorous and thorough.. There is compelling evidence that childhood maltreatment (defined as exposure to emotional, physical, and sexual abuse and neglect before the age of 18 years) is a prominent risk factor for the development of mood disorders as well as for a pernicious course and poor treatment response in mood disorders. These findings, as well as the underlying neurobiological and environmental interactions that may contribute to the development of mood disorders, are examined thoroughly and thoughtfully.. As our understanding of immune function in mood disorders has grown, psychoneuroimmunology has emerged as a focus of study likely to make major contributions to clinical practice in the coming decades. The book updates readers on this promising area of research.
Over the last decade, depression has emerged as the leading cause of disability worldwide, with significant attendant morbidity and mortality. The American Psychiatric Association Publishing Textbook of Mood Disorders equips clinicians and trainees with the knowledge they need to alleviate suffering in their patients with mood disorders.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, D ausgeliefert werden.